Shots:

• The company has completed the enrolment in the P-III APOLLO-B study to evaluate the efficacy & safety of patisiran vs PBO in a ratio (2:1) in 300 patients with ATTR amyloidosis with cardiomyopathy across 90 sites in 20+ countries. The results are expected in mid-2022
• The 1EPs of the trial is the change from baseline in 6 min. walk test @12 mos. The 2EPs is to assess the efficacy on health-related QoL- mortality & cardiovascular events- cardiac biomarkers & manifestations of cardiac amyloid
• Onpattro (Patisiran) is an RNAi therapeutic- approved in US- Canada & Japan for polyneuropathy of hATTR amyloidosis & in EU- Switzerland & Brazil for hATTR amyloidosis with Stage 1 or Stage 2 polyneuropathy

  Ref: Businesswire | Image: Pharmaphorum